| Name | Title | Contact Details |
|---|---|---|
Karen Stringer |
VP, Assistant General Counsel, Deputy Chief Compliance Officer | Profile |
Kristen Galloway |
Vice President and Assistant General Counsel | Profile |
Kristen Greene |
Vice President and Assistant General Counsel | Profile |
Danielle Bello |
Counsel and Director Litigation, Risk and Claims | Profile |
Megan Isaacson |
Associate Director, Legal Operations | Profile |
At Cerebral, we`re on a mission to democratize access to high-quality mental health care. We believe that everyone everywhere deserves to get the care they need, and are striving to make care convenient and accessible, while tackling the stigmas that surround mental illness. Since launching in January 2020, we have gone from a team of 5 to over 4,000 across the United States. With support from investors like SoftBank, Silver Lake, Access Industries, Bill Ackman, WestCap, and others, and impactful leaders like you, we`ll continue to democratize mental health care and double down on clinical quality and deliver exceptional patient outcomes for years to come. With a heavy focus on clinical quality and safety in all that we do, we`ve accomplished excellent patient outcomes: • 82% of patients report an improvement in their anxiety symptoms after using Cerebral. • 75% of patients who report improvement in their depression see improvement within 60 days. • 50% of patients who initially report suicidal ideation no longer harbor suicidal thoughts after treatment with Cerebral. This is just the beginning for Cerebral, and we won`t stop building, growing, and iterating until everyone, everywhere can access high-quality evidence-based mental health care without high costs and/or long wait times. We`re looking for mission-driven leaders who share these values, and we need your help as we transform access to high-quality mental health care in the United States and beyond.
Hawaii Behavioral Health is the leading resource for community-based educational, social, and behavioral health services in Hawaii.
Azopharma Contract Pharmaceutical Services is a Miramar, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. We have initiated two Phase 3b clinical trials of XHANCE for a follow-on indication for the treatment of chronic sinusitis and expect top-line results by the end of 2021 from one trial and in the first half of 2022 from the second trial. If successful, we believe XHANCE would be the first drug therapy product approved by the FDA for the treatment of chronic sinusitis. As of February 28, 2021, we had a total of 204 full-time employees and three part-time employees. A majority of our employees are field-based, in customer-facing roles. Culture is a critical element in the management of our organization. Our talented employees, known as colleagues, are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.
Founded in 1949, Stevanato Group is committed to create systems, processes and services that guarantee the integrity of parenteral medicines. It is comprised of two operational divisions: Pharmaceutical Systems (Ompi and Balda brands): specialized in ready-to-use glass containers and bulk primary packaging (syringes, cartridges, vials, and ampoules); high quality and high precision plastic solutions for diagnostic, pharmaceutical and medical device applications. Engineering Systems (Spami, Optrel, InnoScan and SVM brands): specialized in glass forming technology, inspection systems, assembly, packaging machines and serialization solutions for the pharmaceutical industry. These two divisions enjoy a close, synchronous relationship, featuring daily exchanges which ensure that Stevanato Group has complete control over the entire production process, from purchasing the finest raw materials to offering exceptional after-sales customer service. The Group also benefits from the SG Lab activity that provides technical and analytical services on the potential interaction between the pharmaceutical product and the container.